ABIONYX Pharma SA (EPA:ABNX)
France · Delayed Price · Currency is EUR 3.340
-0.035 (-1.04%)
Oct 7, 2025, 5:35 PM CET
ABIONYX Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 4.33 | 4.55 | 4.64 | 5.25 | 0.68 | - | Upgrade | |
Revenue Growth (YoY) | -10.91% | -1.92% | -11.65% | 678.07% | - | - | Upgrade |
Cost of Revenue | 3.56 | 3.71 | 4.02 | 4.62 | 0.42 | - | Upgrade |
Gross Profit | 0.77 | 0.84 | 0.62 | 0.64 | 0.26 | - | Upgrade |
Selling, General & Admin | 3.73 | 3.43 | 2.61 | 3.66 | 2.34 | 1.27 | Upgrade |
Research & Development | 1.73 | 1.9 | 1.52 | 1.11 | 3.84 | 1.7 | Upgrade |
Other Operating Expenses | -0.02 | -0.02 | -0.1 | -0.02 | 0.04 | - | Upgrade |
Operating Expenses | 5.44 | 5.31 | 4.03 | 4.75 | 6.21 | 2.97 | Upgrade |
Operating Income | -4.67 | -4.47 | -3.41 | -4.11 | -5.95 | -2.97 | Upgrade |
Interest Expense | -0.07 | -0.04 | -0.02 | -0.06 | -0.01 | - | Upgrade |
Interest & Investment Income | 0.09 | 0.1 | 0.06 | 0.01 | 0 | 0.06 | Upgrade |
Currency Exchange Gain (Loss) | 0.02 | -0.03 | -0.04 | 0.04 | -0.02 | 0.04 | Upgrade |
Other Non Operating Income (Expenses) | 0.04 | 0.04 | -0.11 | -0.08 | 0.15 | - | Upgrade |
EBT Excluding Unusual Items | -4.59 | -4.38 | -3.52 | -4.21 | -5.82 | -2.87 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.09 | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.9 | Upgrade |
Pretax Income | -4.59 | -4.38 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade |
Income Tax Expense | 0.01 | - | - | - | - | - | Upgrade |
Net Income | -4.6 | -4.38 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade |
Net Income to Common | -4.6 | -4.38 | -3.52 | -4.21 | -5.82 | -1.89 | Upgrade |
Shares Outstanding (Basic) | 35 | 34 | 29 | 28 | 25 | 23 | Upgrade |
Shares Outstanding (Diluted) | 35 | 34 | 29 | 28 | 25 | 23 | Upgrade |
Shares Change (YoY) | 11.34% | 14.80% | 4.95% | 12.41% | 5.92% | 11.21% | Upgrade |
EPS (Basic) | -0.13 | -0.13 | -0.12 | -0.15 | -0.23 | -0.08 | Upgrade |
EPS (Diluted) | -0.13 | -0.13 | -0.12 | -0.15 | -0.23 | -0.08 | Upgrade |
Free Cash Flow | -3.66 | -3.7 | -3.8 | -3.52 | -6.86 | -0.7 | Upgrade |
Free Cash Flow Per Share | -0.10 | -0.11 | -0.13 | -0.13 | -0.28 | -0.03 | Upgrade |
Gross Margin | 17.78% | 18.55% | 13.32% | 12.11% | 38.37% | - | Upgrade |
Operating Margin | -107.97% | -98.11% | -73.53% | -78.24% | -881.78% | - | Upgrade |
Profit Margin | -106.31% | -96.27% | -75.82% | -80.08% | -862.52% | - | Upgrade |
Free Cash Flow Margin | -84.67% | -81.34% | -81.94% | -67.10% | -1016.00% | - | Upgrade |
EBITDA | -4.56 | -4.34 | -3.27 | -3.99 | -5.83 | -2.95 | Upgrade |
EBITDA Margin | -105.32% | -95.36% | -70.50% | -75.91% | - | - | Upgrade |
D&A For EBITDA | 0.12 | 0.13 | 0.14 | 0.12 | 0.12 | 0.02 | Upgrade |
EBIT | -4.67 | -4.47 | -3.41 | -4.11 | -5.95 | -2.97 | Upgrade |
EBIT Margin | -107.97% | -98.11% | -73.53% | -78.24% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.